For: | Behle N, Kamp F, Proebstl L, Hager L, Riebschläger M, Schacht-Jablonowsky M, Hamdorf W, Neumann S, Krause D, Manz K, Franke AG, Koller G, Soyka M. Treatment outcome, cognitive function, and psychopathology in methamphetamine users compared to other substance users. World J Psychiatry 2022; 12(7): 944-957 [PMID: 36051595 DOI: 10.5498/wjp.v12.i7.944] |
---|---|
URL: | https://www.wjgnet.com/2220-3206/full/v12/i7/944.htm |
Number | Citing Articles |
1 |
Jennifer M. Loftis, Sankrith Ramani, Evan J. Firsick, Rebekah Hudson, Anh Le-Cook, Kevin S. Murnane, Arthur Vandenbark, Renee L. Shirley. Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine. Frontiers in Psychiatry 2023; 14 doi: 10.3389/fpsyt.2023.1259041
|
2 |
Yanan Zhou, Winson Fu Zun Yang, Qiuxia Wu, Yuejiao Ma, Jun Zhou, Honghong Ren, Yuzhu Hao, Manyun Li, Yunfei Wang, Pu Peng, Ning Yuan, Yifan Xiong, Yizhuo Wang, Qianjin Wang, Tieqiao Liu. Altered spontaneous neurological activity in methamphetamine use disorders and its association with cognitive function. Asian Journal of Psychiatry 2024; 94: 103936 doi: 10.1016/j.ajp.2024.103936
|
3 |
Taylor Zande, Albert Kopak, Norman Hoffmann. Multiple diagnoses in the context of parallel epidemics: methamphetamine, opioid use disorder and psychiatric conditions. Journal of Public Mental Health 2024; 23(1): 4 doi: 10.1108/JPMH-09-2023-0076
|
4 |
Sercan Karabulut. A 6-Month Follow-Up Study: Cognitive Impairment May Predict More Frequent Use of Methamphetamine. Substance Abuse: Research and Treatment 2023; 17 doi: 10.1177/11782218231175811
|